Kinnevik B, SE0022060521

Kinnevik reports Q3 NAV growth while Kinnevik B stock falls 7.57 percent

Published on 10/15/2026 at 13:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kinnevik's Q3 NAV rose 1.00 percent to SEK 29.8 billion. Kinnevik B stock costs EUR 5.74 on October 15, 2026, 7.57 percent below the Xetra close.

Kinnevik enters a focused phase

Kinnevik's third-quarter net asset value reached SEK 29.8 billion on October 15, 2026.
The 2027 financial calendar sets the year-end release for February 4, 2027.
Kinnevik B stock trades at EUR 5.74 at 1:17 p.m. CEST at Lang & Schwarz on October 15, 2026, 7.57 percent below the Xetra close of October 14, 2026.

Modernes Glasgebäude am Stockholmer Hafen bei Dämmerung, Symbolbild für Kinnevik AB — Kinnevik AB (ISIN SE0015810247) zeigt modernes Bürogebäude am Wasser, symbolisch für schwedische Investment-Holding bei Dämmerung, Illustration mit AI erstellt.

Kinnevik B (ISIN SE0022060521) was trading at EUR 5.74 at Lang & Schwarz on October 15, 2026 at 1:17 p.m. CEST, down 7.57 percent versus the Xetra close of October 14, 2026 at EUR 6.21. Kinnevik reported third-quarter results on October 15, 2026, with net asset value rising 1.00 percent from the second quarter to SEK 29.8 billion.

NAV growth meets valuation pressure

The report shows a mixed operating picture. Net profit for the third quarter was SEK 218 million, compared with SEK 741 million in the third quarter of 2025. Net asset value fell 17.00 percent during the first nine months of 2026, even though the third quarter itself produced a 1.00 percent increase.

Kinnevik ended September 2026 with net cash of SEK 7.4 billion. The portfolio's value-weighted revenue growth reached 28.00 percent in the first nine months, while EBITDA margins improved by 6.00 percentage points to negative 4.00 percent.

What does the 1.00 percent NAV rise mean?

The quarterly increase came from company growth, financing rounds at Enveda and Tandem Health, and currency effects. Those gains were partly offset by lower valuation multiples and dilution, leaving investors with a narrower margin for valuation optimism.

Enveda's fair value increased 30.00 percent from the second quarter to SEK 1.98 billion, while Tandem Health rose 35.00 percent to SEK 602 million. Kinnevik invested SEK 165 million and completed SEK 183 million of divestments during the quarter.

Three dates define the transition

On August 1, 2026, Helena Saxon assumed the chief executive role, according to the Kinnevik report. On September 30, 2026, net asset value stood at SEK 29.8 billion, and on October 15, 2026, the company published its third-quarter report.

Reporting dates move to 2027

Kinnevik's published financial calendar sets the year-end release for February 4, 2027 and the January to March interim report for April 15, 2027. The dates are listed in the company report.

Stock reaction after the report

The euro quote places Kinnevik B below the Xetra close as investors assess modest NAV growth against the nine-month decline and the portfolio's valuation sensitivity. The current price remains an intraday indication at Lang & Schwarz.

The further course of trading is shown by the continuously updated real-time quote of Kinnevik B stock.